Red X iconGreen tick iconYellow tick icon
Skip to main content

Contact Details

Phone
+64 3 479 8373
Email
matthew.mcneil@otago.ac.nz

University Links

Position
Senior Research Fellow
Department
Department of Microbiology and Immunology
Research summary
Antimicrobial drug resistance

Research

My research is focused on the use of bacterial genetics and functional genomics to investigate bacterial metabolism and antimicrobial drug resistance. Ultimately, the goal of this work is to identify new therapeutics and treatment strategies to combat antimicrobial resistance.

My current work places an emphasis on M. tuberculosis and we are extending these approaches to other bacterial pathogens.

Publications

Adolph, C., Cheung, C.-Y., McNeil, M. B., Jowsey, W. J., Williams, Z. C., Hards, K., Harold, L. K., … Tyndall, J. D. A., … Cook, G. M. (2024). A dual-targeting succinate dehydrogenase and F1Fo-ATP synthase inhibitor rapidly sterilizes replicating and non-replicating Mycobacterium tuberculosis. Cell Chemical Biology, 31(4), 683-698. doi: 10.1016/j.chembiol.2023.12.002 Journal - Research Article

Jowsey, W. J., Cook, G. M., & McNeil, M. B. (2024). Antibiotic resistance in Mycobacterium tuberculosis alters tolerance to cell wall-targeting inhibitors. JAC: Antimicrobial Resistance, 6(3), dlae086. doi: 10.1093/jacamr/dlae086 Journal - Research Article

Cook, G. M., & McNeil, M. B. (2024). Enzyme blueprints will aid tuberculosis drug design. Nature, 631, 278-280. doi: 10.1038/d41586-024-02094-1 Journal - Research Other

Wang, X., Jowsey, W. J., Cheung, C.-Y., Smart, C. J., Klaus, H. R., Seeto, N. E. J., Waller, N. J. E., … Fineran, P. C., Cook, G. M., Jackson, S. A., & McNeil, M. B. (2024). Whole genome CRISPRi screening identifies druggable vulnerabilities in an isoniazid resistant strain of Mycobacterium tuberculosis. Nature Communications, 15, 9791. doi: 10.1038/s41467-024-54072-w Journal - Research Article

Waller, N. J. E., Cheung, C.-Y., Cook, G. M., & McNeil, M. B. (2023). The evolution of antibiotic resistance is associated with collateral drug phenotypes in Mycobacterium tuberculosis. Nature Communications, 14, 1517. doi: 10.1038/s41467-023-37184-7 Journal - Research Article

Back to top